A Phase 2b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of RM-131 Administered to Patients With Vomiting Symptoms and Moderate to Severe Diabetic Gastroparesis

Trial Profile

A Phase 2b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of RM-131 Administered to Patients With Vomiting Symptoms and Moderate to Severe Diabetic Gastroparesis

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Aug 2017

At a glance

  • Drugs Relamorelin (Primary)
  • Indications Diabetic gastroparesis
  • Focus Therapeutic Use
  • Sponsors Rhythm
  • Most Recent Events

    • 05 Aug 2017 Primary endpoint [Effect of RM-131 on vomiting episodes, as assessed in the Diabetic Gastroparesis Symptom Severity Diary (DGSSD)] has not been met, according to the results published in the Gastroenterology.
    • 28 Jul 2017 Results published in the Gastroenterology.
    • 09 May 2017 Results presented at the Digestive Disease Week 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top